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all groups. By the use of 5 spots, we were able to differenti-
ate CJD from AD or NDC with a sensitivity of 100%. CJD could 
also be distinguished from both groups by using a heuristic 
clustering algorithm of 2 spots. We conclude that this pro-
teomic approach can differentiate CJD from other diseases 
and may serve as a model for other neurodegenerative dis-
eases.  Copyright © 2007 S. Karger AG, Basel 
 Introduction 
 Creutzfeldt-Jakob disease (CJD) is a rare and fatal neu-
rodegenerative disease. A definite diagnosis of CJD can 
be made by neuropathologic or immunochemical dem-
onstration of the pathological isoform of the prion pro-
tein (PrP Sc ) in human brain tissue  [1] . Up to now, the in-
tra vitam diagnosis has been made according to clinical 
and electroencephalographic criteria  [2–4] . Attempts to 
detect prion protein aggregates by using fluorescence-
correlated spectroscopy show a sensitivity of only 20% 
 [5] . The clinical diagnosis of CJD can be supported by 
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 Abstract 
 So far, only the detection of 14-3-3 proteins in cerebrospinal 
fluid (CSF) has been accepted as diagnostic criterion for 
Creutzfeldt-Jakob disease (CJD). However, this assay cannot 
be used for screening because of the high rate of false-posi-
tive results, whereas patients with variant CJD are often neg-
ative for 14-3-3 proteins. The aim of this study was to com-
pare the spot patterns of CSF by 2-dimensional polyacrylamide 
gel electrophoresis (2D-PAGE) to search for a CJD-specific 
spot pattern. We analyzed the CSF of 28 patients [11 CJD, 9 
Alzheimer’s disease (AD), 8 nondemented controls (NDC)] 
employing 2D-PAGE which was optimized for minimal vol-
umes of CSF (0.1 ml; 7-cm strips). All samples were run at 
least three times, gels were silver stained and analyzed by an 
analysis software and manually revised. We could consis-
tently match 268 spots which were then compared between 
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biochemical analysis of cerebrospinal fluid (CSF). So far, 
only the 14-3-3 protein immunoblot has been included in 
the diagnostic criteria   [6–9] , despite the fact that other 
surrogate markers also have a high differential diagnostic 
potential and the diagnostic accuracy of 14-3-3 proteins 
was challenged  [10–13] . Especially, this assay cannot be 
used for screening because of the high rate of false-posi-
tive results, whereas patients with variant CJD are often 
negative for 14-3-3 proteins  [12, 13] .
 Initially, 14-3-3 proteins were described as 2 spots 
(P130 and P131) in 2-dimensional polyacrylamide gel 
electrophoresis (2D-PAGE) by Harrington in 1986, which 
he considered at this time to be typical for CJD and her-
pes encephalitis  [14] . Ten years later, again his group 
could sequence at least 1 protein (P130) and identified it 
as a member of the 14-3-3 protein family  [6] .
 Further surrogate markers were found in the CSF of 
CJD patients or patients with other neurological diseases 
applying this approach. For example, elevated ApoE lev-
els in CJD were described  [15] , inter alia an isoform of 
  -antitrypsin in Alzheimer’s disease (AD)  [16] , granin-
like neuroendocrine precursor (proSAAS) in frontotem-
poral dementia  [17] , n- myc oncoprotein in primary brain 
tumors  [18] and apolipoprotein A-IV in schizophrenia 
 [19] .
 So far, this 2D-PAGE approach has barely been used 
for routine diagnosis because of the relatively high amount 
of required CSF, the high time consumption and the low 
sensitivity in comparison to an ordinary SDS-PAGE im-
munoblot if only 1 protein spot is of interest.
 The aim of this study was to compare the entire CSF 
protein pattern of CJD and AD patients and controls in a 
2D-PAGE approach. For this reason, we had to optimize 
our 2D-PAGE setup for a microscale 2-dimensional elec-
trophoresis (2-DE) on minigels with a minimal CSF vol-
ume and in a reasonable analysis time.
 Subjects and Methods 
 Patients 
 We analyzed the CSF of 28 patients who were all diagnosed 
and followed by a specialist neurologist. Eleven patients were di-
agnosed as having CJD, 9 as having AD. The other 8 patients had 
no signs of dementia and served as nondemented control patients 
(NDC).
 According to the clinical criteria, all suspected cases of CJD 
were classified and received at least one cranial computed tomog-
raphy or magnetic resonance imaging before clinical staging to 
exclude ischemic stroke, hemorrhage, or space-occupying lesions 
as a cause of the illness. All patients in this study were classified 
according to the WHO  [7] as having ‘probable’ CJD. Four of these 
patients with CJD were later neuropathologically verified as CJD 
cases. 
 Diagnosis of AD was made according to the established 
NINCDS-ADRDA criteria  [20] .
 The NDC group comprised 8 patients with functional gait dis-
turbance (n = 2), depression (n = 2), left abducens paresis, recur-
rent confusion by chronic urinary infection, lumboischialgia, 
vertigo, and blurred pain syndrome of the limbs. These patients 
had no sign of acute or chronic inflammation or intrathecal im-
mune response in their CSF. No patient of this group had signs of 
cognitive decline.
 Procedures 
 Sample Preparation. Lumbar CSF was taken in approximately 
5-ml portions by the neurologist and sent to our CSF lab. After 
the analysis of the routine parameter, the CSF samples were stored 
at –80  °  C until preparation was performed. All samples have been 
taken in the same way. Prior to 2-DE, to each aliquot of 600   l of 
native CSF 1,200   l ice-cold acetone was added and proteins were 
precipitated overnight at –20  °  C and pelleted by centrifugation 
(10 min at 14,000  g ). The supernatant was discarded and the pel-
let air dried and afterwards resolved in 150   l lysis buffer [9.5  M 
urea, 2% (w/v) CHAPS, 0.8% Pharmalyte pH 3–10 and 1% (w/v) 
DTT]. The solution was vortexed for 15 min in an ultrasound wa-
ter bath. Twenty-five microliters of the 150   l dissolved proteins 
in lysis buffer were later used for each gel. This volume corre-
sponds to 100   l of native CSF. Up to 4 gels were made from each 
patient, which corresponds to 400   l of native CSF.
 Isoelectric Focusing. For isoelectric focusing, commercially 
available linear immobilized pH gradient (IPG) strips were used 
(pH 4–7, 7 cm, Amersham Pharmacia Biosciences). The IPG was 
performed according to Gorg et al.  [21] using the Multiphor-Sys-
tem. The IPG gel strips were rehydrated overnight at room tem-
perature in a solution containing 8  M urea, 0.5% (w/w) CHAPS, 
15 m M DTT and 0.2% (w/v) Pharmalyte (pH 3–10). The rehydrat-
ed strips were loaded with the CSF proteins precipitated from 
100   l, solubilized in 25   l rehydration buffer and focused for 
8,075 Vh.
 Equilibration. After focusing, single strips were equilibrated 
twice for 10 min in 5 ml of equilibration buffer [6  M urea, 2% (w/
v) SDS, 0.72  M bistris, 0.32  M bicine, 30% (v/v) glycerol]. In the 
first equilibration step 50 mg dithiothreitol and in the second step 
240 mg iodoacetamide were added.
 Two-Dimensional Polyacrylamide Gel Electrophoresis. The 
second-dimension separation was performed according to 
Laemmli using the BioRad system with SDS polyacrylamide gels 
consisting of 12% (w/v) total acrylamide monomer. The focused 
gel strips were laid onto the top of the polymerized SDS gels and 
covered by a low-melting agarose buffer [1% (w/v) low-melting 
agarose, 0.25% SDS, 0.36  M bistris, 0.16  M bicine, a trace of brom-
phenol blue] which had previously been heated to melting tem-
perature. After polymerization, gels were run in pairs at 24 mA/
gel at constant current and at room temperature. 
 Gel Staining and Analysis. Proteins were detected by silver 
staining according to Rabilloud  [22] . Stained gels were scanned 
and the image files were imported to the analysis software Image 
master 3.1 (Amersham Biosciences).
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 Results 
 One hundred and nine gels were analyzed from 28 pa-
tient samples. Some of the gels had to be excluded due to 
differences in staining intensities. To reduce the individ-
ual gel-to-gel differences, a minimum of 3 gels was pre-
pared per sample. After excluding unusable gels and sam-
ples with less than 3 gels, 77 gels out of 109 and 26 patients 
out of 28 were left. Of these 26 patients, 9 were suffering 
from CJD and 9 from AD. Samples of 8 patients were used 
as NDC. All data concerning the CSF samples are shown 
in  table 1 .
 An area was selected in which protein spots can be de-
tected easily as isolated instead of blurred spots. This area 
includes spots of a molecular weight between 29 and 
3 kDa, as well as an isoelectric point between 4 and 7.
 All spots in this area were detected by the software 
(Image Master, Amersham Biosciences) and manually 
revised. More than 350 spots were found and 268 spots 
were matched to a reference gel. As a quantitative analysis 
of silver-stained gel is in discussion, analyses were based 
on the presence of spots in the gels.
 Spots of interest were defined as present (intense stain-
ing intensities) in samples of CJD and less present (inten-
sities near background or not visible) in samples without 
CJD ( ! 10%). The conditions were determined as follows: 
first, the lower limit for presence in CJD samples was 85% 
and the upper limit for presence in non-CJD samples was 
20%. The second determination was to differentiate de-
mented (CJD, AD) and nondemented patients by a lower 
limit of 90% in the group of CJD and AD and an upper 
limit of 10% in the group of NDC.
 The first requirement was fulfilled by 3 spots, whereas 
only 1 spot could be found to fulfil the second condition. 
A further spot was present in 38% of AD gels, which was 
also present in 100% of CJD gels, but could rarely be seen 
in NDC gels (9%). In total, we observed 5 spots that ap-
pear to be relevant and differentially expressed in gels of 
patients with CJD, AD or NDC ( table 2 ). These spots were 
isolated locally in the gel and are easy to distinguish from 
other spots. The spots were demonstrated both in the to-
tal map of spots ( fig. 1 ) and in a zoomed area of interest 
( fig. 2 ).
Table 1. Main characteristics of investigated patient groups and CSF samples
Gender
(male/female)
Age
years
14-3-3
positive
Tau protein
pg/ml
S-100B
ng/ml
CJD (n = 9) 4/5 68 (53–83) 9/9 7,478 (1,071–19,208) 9.3 (n = 7) (2.1–14.9)
AD (n = 9) 1/8 64 (52–80) 1/8 759 (359–1,840) 2.06 (n = 4) (1.54–2.74)
NDC (n = 8) 2/6 62 (57–78) n.a. n.a. n.a.
Values are listed as means and range in parentheses. n.a. = Not ascertained.
Spot 87 Spot 100 Spot 162 Spot 213 Spot 230
CJD
Gels (n = 28) 28 (100) 25 (89.3) 28 (100) 25 (89.3) 27 (96.4)
Patients (n = 9) 9 (100) 6 (66.7) 9 (100) 7 (77.8) 8 (88.9)
AD
Gels (n = 28) 24 (93) 4 (15.4) 10 (38.5) 3 (11.5) 4 (15.4)
Patients (n = 9) 9 (100) 3 (33.3) 6 (66.7) 1 (11.1) 2 (22.2)
NDC
Gels (n = 28) 0 (0) 2 (8.7) 2 (8.7) 2 (8.7) 1 (4.4)
Patients (n = 9) 0 (0) 2 (25) 1 (12.5) 2 (25) 1 (12.5)
Figures in parentheses indicate percentages.
Table 2. Detection and percentage of spot 
presence in gels and patients
 Analysis of Cerebrospinal Fluid of 
Patients with Creutzfeldt-Jakob Disease  
Dement Geriatr Cogn Disord 2007;23:22–28 25
 Known proteins were used to extrapolate the molecu-
lar weight and isoelectric point of spots of interest. These 
known proteins were isoforms of haptoglobin [isoelectric 
point 5.7, molecular weight 9,270 Da; serial number of 
SWISS-2DPAGE (http://www.expasy.org/cgi-bin/ch2d-
search-sn): 2D-000CH8], transthyretin (isoelectric point 
5.49, molecular weight 13,800 Da; serial number 2D-
000CFA) and apolipoprotein A1 (isoelectric point 5.22, 
molecular weight 23,149 Da; serial number 2D-000CBM). 
Based on these data, spots of interest were calculated by 
rule of three ( table 3 ).
 Heuristic Clustering 
 Based on the detection of spot 87 and spot 213, we se-
lected the patients according to a heuristic clustering 
( fig. 3 ). First, the gels were split up into groups dependent 
on the detection of spot 87. If they were positive for spot 
87, the samples were clustered into two distinct branches 
by detection of spot 213. After the first splitting, all non-
demented patients and 2 cases with AD were segregated 
to one branch. On the other branch, we found all cases 
with CJD and 23 samples with AD. After the next segre-
gation by spot 213, 25 CJD samples and 3 AD samples 
were clustered to one branch and 3 CJD samples and 21 
AD samples to the other. The AD samples that were clus-
tered after the second splitting to the branch of CJD sam-
ples were only samples from 1 patient. Further CSF anal-
ysis of this patient revealed a similar marker pattern to 
that found in CJD patients (positive 14-3-3 SDS/immu-
noblot and highly elevated tau protein level). All other 
patients with AD could be excluded by clustering the 
samples.
 Only in 3 samples of CJD patients could spot 213 not 
be detected. 
 Single and Combined Diagnostic Sensitivity and 
Specificity 
 All spots were analyzed for sensitivity and specificity. 
The highest sensitivity was obtained for spots 87 and 162 
for CJD, whereas the best specificity was obtained for 
spots 213 and 230. By a combined analysis of these spots 
we obtained higher diagnostic values. The two best com-
binations are shown in  table 4 .
 Discussion 
 The differential diagnosis of dementias is usually 
based upon clinical criteria, while neurochemical data 
are rarely included as diagnostic algorithms. In the case 
of sporadic CJD, the measurement of 14-3-3 proteins in 
CSF was included in the diagnostic criteria by the WHO 
 [6, 7, 14, 23, 24] . However, there is still a need for other 
markers as so far no surrogate marker has been shown to 
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 Fig. 1. Silver-stained 2-DE gel of CJD CSF. 
Proteins are separated by size and charge. 
Spots of interest are marked by arrow-
heads and letters and depicted in figure 2 
(spot A corresponds with spot 100, spot B 
with spot 162, spot C with spot 213, spot D 
with spot 230, spot E with spot 87). pI = 
Isoelectric point; APA1 = apolipoprotein 
A1; TTHY = transthyretin; HPT = hapto-
globin. 
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support the diagnosis sufficiently. Especially patients 
with variant CJD mainly have a negative 14-3-3 immu-
noblot  [12, 25] . Apart from the diagnostic approach, it 
can be doubted that the 14-3-3 proteins play an important 
pathophysiological role in transmissible spongiform en-
cephalopathies  [26] . 
 Our aim was to investigate if a diagnosis can be made 
by a disease-specific spot pattern. This approach is now 
mainly in use for chip-based techniques but is rarely used 
in a 2D-PAGE approach  [27] . As CSF volume is often lim-
CJD spot No. 100 AD spot No. 100 NDC spot No. 100
CJD spot No. 162 AD spot No. 162 NDC spot No. 162
CJD spot No. 213 AD spot No. 213 NDC spot No. 213
CJD spot No. 230 AD spot No. 230 NDC spot No. 230
a
b
c
d
 Fig. 2. Region of silver-stained 2-DE from 
each group demonstrated in one exempla-
ry sample. 
Table 3. Molecular weights and isoelectric 
points of spots found
Isoelectric 
point
Molecular 
weight, kDa
Spot 87 5.33 25.2
Spot 100 6.61 23.7
Spot 162 5.25 19
Spot 213 6.31 11.9
Spot 230 5.66 9.3
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ited, we had optimized the protocol to analyze a minimal 
volume of CSF. In earlier investigations, it was necessary 
to investigate sample volumes between 250   l and 2 ml 
of CSF  [15, 28] . Here we used a volume of only 100   l CSF. 
We concentrated our analysis on an area between 29 kDa 
and 3 kDa and an isoelectric point between 4 and 7 be-
cause proteins with higher molecular weights were not 
clearly separated in this setup with 7-cm strips. Although 
this is a comparably small area, we were able to detect a 
minimum of 268 spots for subsequent analysis. A further 
advantage of these small gels is the minimum of time 
consumption and cost for an analysis. 
 We found 5 protein spots constantly expressed only in 
the CSF of patients suffering from CJD. These spots do 
not match in molecular weight and isoelectric point with 
the currently used markers (14-3-3, tau protein, S-100B, 
NSE). Spot 213 may represent H-FABP, which was cur-
rently identified in the CSF of CJD patients  [29] . Addi-
tionally, none of these spots matched with earlier de-
scribed spots which were found in a similar study  [15] . 
We were not able to validate the spots which were shown 
in this study. This might be due to the small patient 
 number which had been investigated in this former study 
(n = 3)  [15] . 
Table 4. Values for sensitivity (sen) and specificity (spe) of CSF 
spots for clinical diagnosis of CJD
Spot tp, n tn, n fp, n fn, n sen spe
87 28 25 24 0 1 0.54
100 25 43 6 3 0.93 0.81
162 28 37 12 0 1 0.7
213 25 44 5 3 0.93 0.83
230 27 44 5 1 0.98 0.84
87 and 230 27 45 4 1 0.98 0.87
162 and 230 27 45 4 1 0.98 0.87
tp = True positive; tn = true negative; fp = false positive; fn = 
false negative.
 Either by heuristic clustering or by pattern analysis we 
were able to obtain similar values for sensitivity and spec-
ificity, as it was described for currently used biomarkers 
 [12, 30–32] . Certainly, it remains to be seen if these high 
levels of sensitivity and specificity persist when a larger 
number of patients is investigated. As these markers do 
not correspond to the aforementioned CJD biomarkers, 
it will be of special interest to investigate the potential of 
the shown spot pattern in the differential diagnosis of 
variant CJD, as the currently known markers were often 
false negative.
 On the basis of our results, we cannot conclude that 
these spots are involved in the pathophysiology of CJD. 
In further studies with larger amounts of CSF, these spots 
should be attempted to be identified, so that the patho-
physiological function can be investigated. However, this 
does not limit the use of our spot pattern for the diagno-
sis of CJD. 
 In the future, it has to be the goal to generate reference 
gels of special diseases, so that a diagnosis can be made 
by pattern analysis as it has already been described for 
AD  [33] and schizophrenia  [19] .
 
 Fig. 3. Heuristic clustering of CJD versus AD and versus NDC 
 using detection of spot 87 followed by spot 213 by 2D-PAGE. 
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